Chief scientist okays 18 projects

Seven of the projects were in the biotechnology and drug sector for a NIS 12.5m. investment; three were in the medical equipment area for an investment of NIS 7.6m.; four were in software for an NIS 8.4m. investment.

By JERUSALEM POST STAFF
December 11, 2006 08:26

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

The research committee of the Office of the Chief Scientist has approved 18 new projects for a total investment of NIS 40.6 million of which NIS 18.6m. would come from the Chief Scientist's budget, the Ministry of Industry Trade and Labor said Sunday. Seven of the projects were in the biotechnology and drug sector for a NIS 12.5m. investment; three were in the medical equipment area for an investment of NIS 7.6m.; four were in software for an NIS 8.4m. investment. The remainder, for a total investment of NIS 10.6m. were in other areas.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS